Vident Investment Advisory’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Vident Investment Advisory’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-4,833	Closed	-$527K	–	1369
2023 Q1	$527K	Sell	4,833 -98,257	-95%	-$10.9M	0.02%	759
2022 Q4	$11.7M	Buy	103,090 +21,355	+26%	+$1.77M	0.44%	43
2022 Q3	$5.05M	Buy	81,735 +17,593	+27%	+$1.23M	0.16%	164
2022 Q2	$5.12M	Buy	64,142 +9,803	+18%	+$928K	0.15%	168
2022 Q1	$5.72M	Buy	54,339 +14,845	+38%	+$1.45M	0.15%	160
2021 Q4	$4.26M	Buy	39,494 +6,196	+19%	+$676K	0.11%	209
2021 Q3	$3.65M	Sell	33,298 -1,917	-5%	-$199K	0.11%	188
2021 Q2	$3.3M	Buy	35,215 +27,356	+348%	+$2.52M	0.1%	217
2021 Q1	$724K	Buy	7,859 +400	+5%	+$33.8K	0.02%	695
2020 Q4	$545K	Sell	7,459 -1,814	-20%	-$135K	0.02%	693
2020 Q3	$720K	Buy	+9,273	New	+$638K	0.04%	579
2016 Q4	–	Sell	-24,351	Closed	-$441K	–	401
2016 Q3	$441K	Sell	24,351 -54,890	-69%	-$1.07M	0.06%	378
2016 Q2	$1.3M	Sell	79,241 -163,369	-67%	-$2.64M	0.18%	253
2016 Q1	$4.02K	Buy	242,610 +61,948	+34%	+$1.08M	0.25%	201
2015 Q4	$3.92M	Sell	180,662 -78,463	-30%	-$1.53M	0.5%	8
2015 Q3	$5.14M	Buy	259,125 +142,173	+122%	+$4.49M	0.71%	6
2015 Q2	$4.06M	Buy	116,952 +43,849	+60%	+$1.34M	0.54%	12
2015 Q1	$1.9M	Buy	+73,103	New	+$1.34M	0.38%	27

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vident Investment Advisory's HZNP Position: Q2 2023 in Review

Vident Investment Advisory sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2023, closing a stake of 4,833 shares — an estimated $527K sold.

Vident Investment Advisory first reported a position in HZNP in Q1 2015 and held it in 18 quarters. The position peaked at $11.7M in Q4 2022. 519 funds tracked by Wall St. Rank hold HZNP as of Q2 2023.

Vident Investment Advisory reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2023 after selling out during the quarter.
Vident Investment Advisory sold 4,833 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2023, an estimated $527K.
Vident Investment Advisory first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2015 and held it in 18 quarters.
Vident Investment Advisory's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $11.7M in Q4 2022.
519 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2023.

Based on Vident Investment Advisory's 13F filing for Q2 2023, filed 11 Aug 2023.